EMEA-000980-PIP04-18

Key facts

Invented name
Adcetris
Active substance
Brentuximab vedotin
Therapeutic area
Oncology
Decision number
P/0327/2018
PIP number
EMEA-000980-PIP04-18
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Mature T and NK neoplasms (excluding anaplastic large-cell lymphoma and cutaneous Tcell lymphoma)
Route(s) of administration
Intravenous use
Contact for public enquiries
Takeda Pharma A/S

Tel. +44 2031168000
E-mail: paediatrics@tgrd.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating